SBI Term Loan: RLLR: 8.15 | 7.25% - 8.55%
Canara Bank: RLLR: 8 | 7.15% - 9.85%
ICICI Bank: RLLR: -- | 8.5% - 9.65%
Punjab & Sind Bank: RLLR: 7.3 | 7.35% - 10.75%
Bank of Baroda: RLLR: 7.9 | 7.2% - 8.95%
Federal Bank: RLLR: -- | 7.35% - 9.6%
IndusInd Bank: RLLR: -- | 7.6% - 10%
Bank of Maharashtra: RLLR: 8.05 | 7% - 9.15%
Yes Bank: RLLR: -- | 7.4% - 10.54%
Karur Vysya Bank: RLLR: 8.8 | 8.5% - 10.65%
HDFC Bank: RLLR: -- | 7.75% - 13.2%
Axis Bank: RLLR: -- | 8% - 9.1%
IDBI Bank: RLLR: -- | 7.4% - 10%

Sahajanand Medical Technologies IPO closes with 14.20 times subscription as QIB demand leads bidding

#Taxation & Finance News#Commercial#India
Synopsis

Sahajanand Medical Technologies Ltd, a cardiac stent manufacturer, received 14.20 times subscription for its INR 475 crore initial public offering (IPO) on the final day of bidding. Qualified institutional buyers (QIBs) subscribed 34.70 times their reserved portion, followed by non-institutional investors at 14.64 times and retail investors at 3.03 times. The company raised INR 140 crore from anchor investors before the issue. The IPO is entirely an offer for sale by existing shareholders, with no fresh issue. Listing on the BSE and NSE is proposed for 23 October, at a price band of INR 327–344 per share.

Sahajanand Medical Technologies Ltd’s INR 475 crore initial public offering (IPO) closed with 14.20 times subscription on Monday, as demand across investor categories exceeded the number of shares available. The cardiac stent manufacturer received bids for 1,384,727,771 shares against 97,50,482 shares on offer, according to data from the National Stock Exchange (NSE). The offering was priced in the band of INR 327–344 per share, with the company’s equity shares proposed to be listed on the BSE and NSE on 23 October. 
Qualified institutional buyers (QIBs) accounted for the strongest demand, subscribing to their reserved portion 34.70 times. The non-institutional investor category received 14.64 times subscription, while retail investors subscribed to their portion 3.03 times. The figures show that institutional investors recorded the highest subscription multiple, with participation across all three investor categories exceeding the shares allocated to them. Ahead of the public offering, Sahajanand Medical Technologies raised INR 140 crore from anchor investors on Wednesday. Anchor investors are institutional participants allotted shares before the public subscription period begins. Their participation forms part of the overall IPO allocation and precedes the final listing process. 
The IPO is entirely an offer for sale (OFS) of up to 1.38 crore equity shares by existing shareholders. It does not include a fresh issue of shares. As a result, the company will not receive any proceeds from the public offering, with the sale proceeds accruing to the shareholders selling their holdings. Unlike a fresh issue, which can provide capital for business expansion, manufacturing investments or working capital, an OFS primarily enables existing shareholders to sell part of their stake to public market investors. 
Sahajanand Medical Technologies manufactures cardiac stents, medical devices used to help keep narrowed or blocked arteries open. The company operates in the medical technology sector, which supplies products used in cardiovascular procedures and other clinical applications. Demand for its public offering was recorded across institutional, non-institutional and retail investor segments during the subscription period. 
Based on the reported figures, bids at the upper end of the price band would represent an indicative value of approximately INR 4,760 crore. This is a derived estimate based on the number of shares bid for and the INR 344 upper price limit, rather than an officially reported monetary value of applications. With bidding concluded, the next scheduled milestone is the proposed listing on 23 October. The final subscription level reflects investor demand during the IPO period, while the offer-for-sale structure means the transaction does not provide fresh equity capital to Sahajanand Medical Technologies itself. 
Source PTI

Discussion

Have something to say? Post your comment